VeriStrat Development and Validation Data
VeriStrat is a validated serum test that identifies patients as either VeriStrat Good or VeriStrat Poor.
VeriStrat was developed and validated in a study of 460 patients from 8 independent cohorts, involving 8 institutions. The study findings have been published in the Journal of the National Cancer Institute (JNCI). The test was developed using the analysis of pre-treatment serum from a training set of samples collected from 139 patients. The training sample sets were obtained from 3 independent cohorts of patients in Italy and Japan who were treated in second or subsequent lines of therapy with the EGFR tyrosine kinase inhibitor (EGFR-TKI) gefitinib. The samples analyzed for the validation sets were from a cohort of patients in Italy treated with gefinitib and a cohort from the ECOG 3503 trial treated with erlotinib.
Below is a summary of the JNCI study. For the full article content click here.
VERISTRAT PROVIDES A CLEAR TEST RESULT, VERISTRAT GOOD OR VERISTRAT POOR, THAT CORRELATES WITH SURVIVAL OUTCOMES AFTER EGFR-TKI THERAPY
*Data and figures have been updated since publication in Taguchi et al.1
PATIENTS CLASSIFIED AS VERISTRAT GOOD SHOWED A SIGNIFICANT INCREASE IN OVERALL SURVIVAL FOLLOWING EGFR-TKI THERAPY AS COMPARED TO PATIENTS CLASSIFIED AS VERISTRAT POOR. DATA SUGGEST THAT:
- Patients classified as VeriStrat Good may be considered for EGFR-TKI therapy
- Patients classified as VeriStrat Poor may be considered for non-EGFR-TKI therapy
VERISTRAT DOES NOT CORRELATE WITH OUTCOMES FOR PATIENTS TREATED WITH CHEMOTHERAPY OR SURGERY ALONE
*Data and figures have been updated since publication in Taguchi et al.1
SUBSET ANALYSIS: VERISTRAT CORRELATES WITH OUTCOMES REGARDLESS OF CLINICAL CHARACTERISTICS
Patients with a history of smoking
- VeriStrat identifies candidates for EGFRI therapy that may otherwise be excluded based on a history of smoking
Patients with squamous cell tumors
- VeriStrat identifies patients that may otherwise be excluded for EGFR-TKI therapy based on squamous cell histology
VeriStrat Scientific Presentation (PDF)
1. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007;99:838-846.
